HyperGRO™: Plasmid DNA Manufacturing Platform
1
HyperGRO™Plasmid Fermentation Reduced metabolic burden Toxic/unstable plasmid production Up to 3.5 g/L volumetric yield Sublicensed to CMOs for cGMP
e.g. Aldevron, Eurogentec, VGXI, Leidos
Antibiotic-free Expression Vector kits
NTC Technologies & Services Synthetic Gene Design/Contract Cloning Antibiotic-free vector backbone retrofit
NTC8 Series
Transgene
RNA-OUT
pUC origin
Plasmid Manufacture
2
HyperGRO™: Industry Leading Scalability of Plasmid Vectors Proprietary fed-batch bacterial
fermentation process
Produces up to 10x the yield oftypical processes
Dramatically improves thescalability of plasmid productioncompared with traditionaltechniques
Results in the production of moreusable, high quality plasmid forgene therapy and DNA vaccinepurposes, without increased cost
Up to 3.5 g/L plasmid yield
Licensed to 5 cGMP CMOs
0
500
1000
1500
2000
2500
3000
Shake flask Typicalfermentation
proceses
HyperGRO™
Pla
smid
yie
ld (m
g/L)
3
High Yield Manufacture Three cGMP facilities have successfully utilized NTC’s HyperGRO™
fermentation process for high yield manufacture of NTC’s RNA-OUT Vectors
4
Three Pronged Business Strategy Creating valuable IP enabling gene-based drugs
• 12 Granted US Patents• 8 Pending US Patent Applications
Providing design, development and manufacturingof gene-based medicines to industry partners
Technology transfer and licensing• HyperGRO™ plasmid fermentation process - 5 licensed
CMOs• NTC RNA-OUT Marker vectors - 7 licensed vector users• Nanoplasmid™ vectors - >20 Biotech/Pharma companies
evaluating
5
Plasmid Production Platform: Intellectual Property
Granted US Patent 6
High specific yield
High biomass yield
Generic platform: compatible with many different plasmids and antigen gene inserts
Reduce cost
Plasmid Manufacturing Goals
7
Medium composition C:N ratio Trace minerals
Metabolic burden & cell stress High copy number plasmid Plasmid encoded protein over-expression (e.g.
kanR gene product)
Process Factors
8
Initial temperature 30°C for minimum plasmid copy number during biomass accumulation Reduces copy number and metabolic burden
Temperature shift 30°C 42°C during nutrient limited growth to induce high copy number plasmid production Slow growth, low protein expression reduces metabolic burden
HyperGRO™ Inducible Fed-Batch ProcessDesigned for temperature sensitive pUC origin-containing plasmids
Carnes and Williams. US Patent 7,943,377; EP1781800 (multiple international equivalents) Carnes et al. (2011) Biotechnol Bioeng 108: 354 Williams et al. (2009) Biopharm Int 22: 46 Williams et al. (2009) Biotechnol Bioeng 103:1129 Carnes et al. (2006) Biotechnol Appl. Biochem 45:155
9
Time
X(t), T(t)
μ = μmax
X(t) V(t)
F(t)
μ = 0.12 h-1
Batch phase Fed-batch phase Sf
F(t)=F0eµt
30°C
42°C Step shift Cell density
Slow ramp
HyperGRO™ Inducible Fed-Batch Process
10
1
10
100
1000
10000
0 5 10 15 20 25 30 35 40 45 50
Cultivation time
OD
600,
mg/
L
0.00
2.00
4.00
6.00
8.00
10.00
12.00m
g/L/OD
600
Cell density (OD600)
Overall Plasmid Yield (mg/L)
Specific Plasmid Yield(mg/L/OD600)
E. coli DH5α/gWizGFP Fed-batch 30 42°C shift at 35 hours
HyperGRO™ pDNA Fermentation Plasmid:1100 mg/L - Biomass: OD600 111
11
E. coli DH5α/NTC7485 Fed-batch 30 42°C 2130 mg pDNA/L
HyperGRO™ pDNA Fermentation
12
Analysis indicated 98.7% supercoiled plasmid in final sample
Plasmid Quality Analysis GE Healthcare Plasmid Select Xtra analysis
13
Inducible Fed-batch process enables productionof plasmids with direct or inverted repeats (e.g.Retroviral vectors) and unstable, dimerization-prone sequences (e.g. Multiple shRNA vectors)
Unstable plasmids are stabilized by maintaininglower copy number at 30°C during biomassgrowth
Yield increased by temperature shift prior toharvest
Production of unstable plasmids
14
M) 1 kb DNA Ladder1) Seed culture 30-42°C
2) 30°C, 24 OD600, 28 mg/L3) 30°C, 33 OD600, 41 mg/L4) 42°C, 81 OD600, 680 mg/L5) 25°C, 70 OD600, 695 mg/L
37ºC Process
M 1 2 3 4 5 6 7 8 9
VLTrap stabilization using 30-42°C inducible process:
6) 37°C, 10 OD600, 64 mg/L7) 37°C, 13 OD600, 90 mg/L8) 37°C, 15 OD600, 83 mg/L9) 37°C, 90 OD600, 214 mg/L
(Arrow denotes deletion product arising from LTR recombination in 37°C process)
Production of unstable plasmids
15
Process
Yield Quality
Viability (seed stock toxicity)
Plasmid Intrinsic FactorsOrientation/composition of vector elements
16
Process must also consistently produce acceptable amounts of suboptimal plasmids, or plasmids with suboptimal inserts (e.g. inserts designed de novo from emerging pathogen sequences) Toxic proteins or peptides from cryptic promoters
Unusual DNA structures (Z-DNA, triplex)
Plasmid Factors: Intrinsic Poor Yield
17
Reduce cell stress during creation of seed banks and during the fermentation process
Example:
Influenza hemagglutinin (HA) genes from H1, H3, and H5serotypes evaluated
Genes from H1 and H3 serotypes are known to lower plasmidyields
Seed banks were created at 30°C and 37°C and evaluated infermentation
Overcoming Plasmid-Intrinsic Poor Yield
18
† H1 and H5 are in pDNAVACCUltra backbone. H3 is in gWiz-D backbone. * Fermentation yield from 30°C glycerol stock with H3 antigen in pDNAVACCUltra backbone was 1005 mg/L.
Plasmid antigen†
Glycerol stock preparation temp.
Glycerol stock viable
Fermentation yield (mg/L)
H1 influenza 30°C Yes 252
37°C No Inviable cell line
H3 influenza 30°C Yes 570 * 37°C No Inviable cell line
H5 influenza 30°C Yes 1290
37°C Yes 1260
Effect of cell banking temperature:
Overcoming Plasmid-Intrinsic Poor Yield
19
Time
X(t)
μ = μmax
X(t) V(t)
F(t)
μ = 0.12h-1
Batch phase
Fed-batch phase
Sf
S≈0
T = 30-42°CpH = 7.0DO = 30%
Reduced temp Temp induction
Scale up: 300L GE Healthcare Uppsala, Sweden
20
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0 10 20 30 40 50
Hours
OD
600,
mg/
L
0
2
4
6
8
10
12
14
16
18
20
mg/L/O
D600
Biomass, OD600
Plasmid, mg/L
Plasmid, mg/L/OD600
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0 10 20 30 40 50
HoursO
D60
0, m
g/L
0
2
4
6
8
10
12
14
16
18
20
mg/L/O
D600
Biomass, OD600
Plasmid, mg/L
Plasmid, mg/L/OD600
10 L 300 L
Scale up: 10L to 300L Plasmid Yield Time Course
21
Scale 10 L 300 L Volumetric
plasmid yield 1560 mg/L 1184 mg/L
Specific plasmid yield 16.6 mg/L/OD600 16.9 mg/L/OD600
Cell density 93 OD600 71 OD600
Scale up: Yield Summary
22
Used for GMP production of DNA vaccines by NIH’s0Vaccine Research Center (VRC)Yields > 1 g/L at 50 L & 100 L scale
VRC DNA Vaccine Production
23
0
500
1000
1500
2000
2500
3000
0
20
40
60
80
100
120
140
0 5 10 15 20 25 30 35 40 45 50
plasmid (m
g/g)Biom
ass (
OD6
00)
Spec
ific
plas
mid
(m
g/g
DCW
EFT (hours)
Biomass (OD600)
Specific plasmid (mg/g DCW) Plasmid (mg/L)
A B
HyperGRO™ Production of VRC pDNA
A. Growth and volumetric and specific plasmid yield from an NTC 10L DH5α/VRC2439fermentation starting from 30°C transformed cell bank Temperature was shifted from 3042°C at 30 h EFT.
B. Analysis of Harvest plasmid sample by 1% agarose electrophoresis; left lane: 1kb PlusDNA Ladder (Invitrogen), right lane: 1µg VRC2439 plasmid from harvest sample.
24
Nelson et al. (2013), Hum Vaccin Immunother 9:2211
Antibiotic-free HyperGRO™ fermentation: cGMP plasmid
VGXI, Inc., utilized cGMP fermentation with NTC’s HyperGRO™ fermentation platform to manufacture Admedus’s Herpes Simplex Virus 2 DNA vaccine for their Phase I clinical trial.
VGXI achieved reproducible plasmid yields of up to 1.8 g/L at the 320L scale without the use of antibiotic selection
25
NTC9385R Nanoplasmid™Scalable high yield Manufacturin g using HyperGRO™ Fermentation
NTC9385R Nanoplasmid™ vector growth and plasmid yield profile of a 10L HyperGRO™ fed-batch fermentation using slow ramp temperature induction. Peak Nanoplasmidyield of 2420 mg/L.
26
3042°C
High plasmid yields up to 3.5 g pDNA/L
High specific plasmid yields up to 25 mg/L/OD600, 50 mg pDNA/g DCW (5% of total)
High productivity: up to 50 mg/L/hour
Compatible with NTC’s antibiotic-free sucrose selection
Low metabolic burden processimproved production with unstable & toxic plasmids
Scaled to 100 L & 320 L GMP production at >1 g/L
HyperGRO™ Key Advantages
27
Currently licensed for use at GMP facilities in the USA, includingthe VRC and four CMOs, and GMP facilities in Europe and India
Research grade pDNA manufacturing at NTC and GMP productionof clinical grade by HyperGRO licensee provides customer withprocess continuity
HyperGRO™ Licensing and Tech Transfer
28
NTC Autolytic Plasmid DNA Manufacturing Platform
29
Alkaline lysis Widely used in laboratories Scale-up issues (specialized mixing) Large volumes
Lysis technology for plasmid purification
30
Lysozyme/heat lysis Lower volume
Efficient plasmid recovery requires addition ofrecombinant lysozyme
Availability of recombinant lysozyme would be anissue for production of a DNA vaccine in apandemic situation*
Hoare M, et al. Biotechnol Prog 2005; 21:1577-1592.
Lysis technology for plasmid purification
31
Compatible with NTC’s inducible fed-batch plasmid fermentationprocess
High yielding plasmid production strains express chromosomallyencoded lysozyme
o Phage λ endolysin
o Heat inducible promoter(no inducer required when used withNTC’s inducible fed-batch plasmid fermentation process
o Cytoplasmic production(no lysis during fermentation)
Autolysis of harvested cells resuspended in membranepermeabilizing buffers
NTC plasmid production in autolytic E. coli host strains
32
0
2
4
6
8
10
12
14
16
18
20
0
500
1000
1500
2000
2500
0 10 20 30 40 50
mg/L/O
D600 O
D60
0, m
g/L
EFT
Biomass, OD600
Plasmid, mg/L
Plasmid, mg/L/OD600
0
2
4
6
8
10
12
14
16
18
20
0
500
1000
1500
2000
2500
0 10 20 30 40 50
mg/L/O
D600 O
D60
0, m
g/L
EFT
Biomass, OD600
Plasmid, mg/L
Plasmid, mg/L/OD600
RF 546: NTC4862 (DH5α SacB host) RF 547: NTC3016 (autolytic DH5α SacB host)
137 OD6002.2 g pDNA/L 6.3 mg pDNA/g WCW
125 OD6001.9 g pDNA/L 6.6 mg pDNA/g WCW
High yield in HyperGRO™ NTC8 series AF vector is produced at similarly high
yields in non-autolytic and autolytic hosts.
33
0
5
10
15
20
25
30
35
0
500
1000
1500
2000
2500
3000
3500
4000
0 5 10 15 20 25 30 35 40 45 50
mg/L/O
D600 O
D60
0, m
g/L
EFT
Biomass, OD600
Plasmid, mg/L
Plasmid, mg/L/OD600
117 OD6003.5 g pDNA/L 9.9 mg pDNA/g WCW
RF 561: NTC8 series AF vector in NTC3016 (autolytic DH5α SacB host)
High yield in HyperGRO™ NTC8 series AF vector is produced at record high yield of 3.5 g/L
34
Autolysis of harvested cells
DH5α
DH5α with 500 U/ml Epicentre
Ready-Lyse™Lysozyme
NTC autolytic
plasmid host
30 OD600 resuspensions and 30 minutes at room temperature: STET buffer 8% glucose, 50 mM TrisHCl, 50 mM EDTA, 2% Triton X-100
35
Autolytic cells are resuspended under low salt, acidic conditions to release the cytoplasmic endolysin and permeabilize the cell wall to plasmid DNA without complete cell lysis.
PeptidoglycanDisrupted by endolysin(e.g. λ R) or lysozyme
Outer membraneDisrupted bypermeabilizer(e.g. EDTA)
Inner membraneDisrupted by detergent(e.g. Triton X-100)
Bacterial chromosome
Plasmids1. Resuspend cell paste with 20
volumes Autolytic AcidicExtraction Buffer (30mMsodium acetate, 10 mM EDTA,8% sucrose, pH 5.2).
2. Add Triton X-100 to 0.1% andstir for 30 minutes at roomtemperature.
3. Remove cell debris/gDNAbysolid/liquid separation andrecover the pDNA-containingsupernatant.
Carnes AE, Hodgson CP, Luke JM, Vincent JM, Williams JA. Plasmid DNA production combining antibiotic-free selection, inducible high yield fermentation, and novel autolytic purification. Biotechnol Bioeng. 2009 Oct 15;104(3):505-15
Acidic Autolytic Plasmid Extraction
36
• 2 grams RF 547cell paste = 13.2mg pDNA
• 40 mL AutolyticAcidic Extraction,30 minutes
• Centrifuged 30min at 4000 x g.
• Recoveredsupernatant
• Adjusted to 0.6MNaCl and 1% TritonX-100
• Purified overGiga-scale weakanion exchangecolumn
• Final yield:8.4 mg pDNAA260/A280 = 1.8 64%purification yield
1 µg of the purified pDNA on agarose gel
From fermentation RF 547:NTC8 series AF vector in NTC3016 (autolytic DH5α SacB host)
Small Scale Test Purification
37
Example Large Scale Process
38
Step Volume (mL)
DNA conc. (mg/mL)
Total DNA (mg)
pDNA (%)
gDNA (%)
pDNA recovery (%)
Autolytic acidic extraction (30 min), 30 min 12,000g centrifugation.
1000 0.228 228 98.61% 1.39% 69%
KDS protein removal, 30 min 12,000g centrifugation.
1176 0.233 274 99.25% 0.75% 82%
Mustang Q (10 mL capsule, 2 cycles) anion exchange
544 0.498 271 99.66% 0.34% 82%
LRA impurity adsorption & buffer exchange to TE
100 2.2 220 99.7% 0.30% 66% overall downstream yield
Large scale autolytic purification From fermentation RF 547:NTC8 series AF vector in NTC3016 (autolytic DH5 α SacB host) 50 g fermentation cell paste = 331 mg pDNA
39
Large scale autolytic purification
1 2 3 4 5 6 7 8 9 10
Agarose gel electrophoresis of process samples
1. 1 kb DNA ladder2. Extract after cell debris removal3. Extract after KDS precipitation4. Mustang Q lysate flow through (cycle 1)5. Mustang Q wash (cycle 1)6. Mustang Q lysate flow through (cycle 2)7. Mustang Q wash (cycle 2)8. 1 kb DNA ladder9. 1 µg of miniprep purified pDNA from initial
extract shown in lane 210. 1 µg of final large scale purified pDNA
40
Acidic Autolytic Extraction vs. Alkaline Lysis
Standard Alkaline
Lysis
Modified Alkaline
Lysis
Autolytic Acidic
Extraction
Total reagent mass (kg) 4.32 13.03 0.17
Total lysate volume (L) 30 100 20
Total lysis reagent cost $93.79 $173.73 $8.95
Dramatic reduction in raw materials and lysis volumes
Reduce cost by 90%, reagent mass by 96%, lysate volume by 33%versusstandard alkaline lysis Reduce cost by 95%, reagent mass by 99%, lysate volume by 80%versusmodified alkaline lysis (used for Mustang Q processing) Potentially 2x final yield vs. alkaline lysis processes (NTC historical data)
41